OA-55 Iberdomide, Daratumumab, and Dexamethasone (IberDd) in Transplant-Ineligible (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Results From the CC-220-MM-001 Trial

IF 2.7 4区医学 Q2 HEMATOLOGY Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI:10.1016/S2152-2650(24)01896-2

Anna Sureda Balari, Abdullah Khan, Albert Oriol, Mercedes Gironella Mesa, Faiz Anwer, Cristina Encinas Rodríguez, Brea Lipe, Paula Rodríguez-Otero, Michael Amatangelo, Kexin Jin, Thomas Solomon, Lilia Taningco, Alpesh Amin, Paulo Maciag, Sagar Lonial

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

OA-55伊博多肽、达拉单抗和地塞米松（IberDd）治疗不符合移植条件（TNE）的新诊断多发性骨髓瘤（NDMM）：CC-220-MM-001试验结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.